# Optimizing Lymphodepletion to Improve Outcomes in Patients Receiving Cell Therapy With Kymriah

> **NCT06003179** · PHASE1 · WITHDRAWN · sponsor: **University Health Network, Toronto**

## Conditions studied

- Lymphoma, Large B-Cell, Diffuse

## Interventions

- **DRUG:** Cyclophosphamide
- **RADIATION:** TLI
- **DRUG:** Fludarabine

## Key facts

- **NCT ID:** NCT06003179
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-04-05
- **Primary completion:** 2026-11
- **Final completion:** 2028-11
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** recruitment challenges and sites who initially expressed interest declined.
- **Last updated:** 2024-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06003179

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06003179, "Optimizing Lymphodepletion to Improve Outcomes in Patients Receiving Cell Therapy With Kymriah". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06003179. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*